Pluristem Therapeutics’ (PSTI) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Pluristem Therapeutics (NASDAQ:PSTI) in a report published on Wednesday morning, AnalystRatings.com reports. They currently have a $15.50 price objective on the biotechnology company’s stock.

Several other equities analysts have also recently issued reports on the stock. Zacks Investment Research raised shares of Pluristem Therapeutics from a hold rating to a buy rating and set a $4.25 price objective on the stock in a research note on Thursday, October 17th. LADENBURG THALM/SH SH started coverage on shares of Pluristem Therapeutics in a research note on Monday, July 22nd. They issued a buy rating on the stock. Finally, ValuEngine cut shares of Pluristem Therapeutics from a buy rating to a hold rating in a research note on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Pluristem Therapeutics currently has a consensus rating of Buy and a consensus target price of $9.25.

Get Pluristem Therapeutics alerts:

Shares of NASDAQ PSTI traded up $0.03 during midday trading on Wednesday, hitting $3.23. The company’s stock had a trading volume of 23,200 shares, compared to its average volume of 72,100. Pluristem Therapeutics has a 1-year low of $3.17 and a 1-year high of $11.90. The firm’s fifty day moving average price is $3.55 and its 200-day moving average price is $2.47. The company has a current ratio of 2.74, a quick ratio of 3.23 and a debt-to-equity ratio of 0.07.

Several institutional investors and hedge funds have recently made changes to their positions in PSTI. ARK Investment Management LLC increased its position in shares of Pluristem Therapeutics by 35.9% in the second quarter. ARK Investment Management LLC now owns 5,156,645 shares of the biotechnology company’s stock worth $32,007,000 after acquiring an additional 1,363,396 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of Pluristem Therapeutics by 107.3% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,882,401 shares of the biotechnology company’s stock worth $1,168,000 after acquiring an additional 974,306 shares in the last quarter. Nikko Asset Management Americas Inc. increased its position in shares of Pluristem Therapeutics by 102.8% in the second quarter. Nikko Asset Management Americas Inc. now owns 1,882,401 shares of the biotechnology company’s stock worth $1,168,000 after acquiring an additional 954,161 shares in the last quarter. Verition Fund Management LLC purchased a new position in shares of Pluristem Therapeutics in the second quarter worth approximately $231,000. Finally, Jane Street Group LLC increased its position in shares of Pluristem Therapeutics by 28.1% in the second quarter. Jane Street Group LLC now owns 153,322 shares of the biotechnology company’s stock worth $95,000 after acquiring an additional 33,630 shares in the last quarter. 71.33% of the stock is currently owned by institutional investors.

About Pluristem Therapeutics

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Featured Story: Swap

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.